Merus N.V. MRUS
Set alert
90.00 USD 0.00 0.00%
As of Jan 2, 9:30 AM ET
90.00 Day range 90.00
52-week range unavailable
- YTD
- 0.00%
- 1 year
- +112.77%
- Open
- 90.00
- Prev close
- 90.00
- Mkt cap
- 6.83B
- Vol
- 2.72M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 90.00
- High
- 90.00
- Forward P/E
- -17.65
- Beta
- 1.06
- Short ratio
- 0.59
- Inst. own
- 92.80%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 95.41
- 200-d avg
- 69.34
- 1y target
- 97.00
2Y chart
Events in this range
- Sep 30, 2025Downgrade: LifeSci Capital · Outperform → Market Perform
- Sep 30, 2025Downgrade: UBS · Buy → Neutral
- Sep 30, 2025Downgrade: Wells Fargo · Overweight → Equal-Weight
- Sep 30, 2025Downgrade: Canaccord Genuity · Buy → Hold
- Sep 30, 2025Downgrade: Guggenheim · Buy → Neutral
- Oct 6, 2025Downgrade: Leerink Partners · Outperform → Market Perform
Signals (73)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| MACD: Sell Signal | Oct 16, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| RSI: Overbought | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 16, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 11, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 6, 2025 | 1 year ago |
| RSI: Overbought | Aug 4, 2025 | 1 year ago |
| RSI: Overbought | Jul 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 12, 2025 | 1 year ago |
| RSI: Overbought | Jun 3, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| RSI: Overbought | May 23, 2025 | 1 year ago |
| SMA: Bearish | May 22, 2025 | 1 year ago |
| SMA: Bullish | May 20, 2025 | 1 year ago |
| MACD: Buy Signal | May 20, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
Newest 20 of 73.
Key statistics
- Market cap
- 6.83B
- Enterprise value
- 6.20B
- Trailing P/E
- 0.00
- Forward P/E
- -17.65
- PEG ratio
- 0.00
- Price / sales
- 120.59
- Price / book
- 8.81
- EPS (TTM)
- -5.28
- Beta
- 1.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 56.61M
- Revenue growth
- 3.20%
- Free cash flow
- -174.43M
- Total cash
- 635.93M
- Total debt
- 12.32M
- Return on equity
- -51.57%
- Shares outstanding
- 75.85M
- Short % of float
- 1.08%
- 50-day average
- 95.41
- 200-day average
- 69.34
Analyst view
Consensus: hold
Hold
Price target (mean) 97.00
Ratings (0m) 10 1 buy · 9 hold · 0 sell
- Strong buy0
- Buy1
- Hold9
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.99344.
Financials — quick view
MRUS Revenue — quarterly 12.15M
MRUS Net income — quarterly -95.52M
MRUS EPS — quarterly -1.26
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Sep 30, 2025 | Guggenheim | down | Buy | Neutral |
| Sep 30, 2025 | Canaccord Genuity | down | Buy | Hold |
| Sep 30, 2025 | Wells Fargo | down | Overweight | Equal-Weight |
| Sep 30, 2025 | UBS | down | Buy | Neutral |
| Sep 30, 2025 | LifeSci Capital | down | Outperform | Market Perform |
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- merus.nl
News
- 10 Health Care Stocks Whale Activity In Today's Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Tilray Brands, SNDL, Innoviz Technologies, Pony AI And Other Big Stocks Moving Higher On Monday
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
- CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio?
- This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
- This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Your note
Sign in to keep a note on MRUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKKER LEX B H | Officer | Conversion of Exercise of derivative security | Jul 1, 2021 | 15,668 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 1, 2021 | 0 |
| BVF PARTNERS L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 7, 2021 | 0 |
| DE KRUIF JOHN | Chief Technology Officer | Sale | Aug 11, 2021 | 15,282 |
| GENMAB AS | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 25, 2025 | 0 |
| IWICKI MARK T. | Director | Conversion of Exercise of derivative security | Apr 13, 2023 | 73,576 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 5.77% | 4,373,770 | 393.64M | Sep 29, 2025 |
| Avoro Capital Advisors LLC | 4.67% | 3,542,500 | 318.82M | Sep 29, 2025 |
| Commodore Capital Lp | 4.65% | 3,525,000 | 317.25M | Sep 29, 2025 |
| Deerfield Management Company, L.P | 4.02% | 3,046,916 | 274.22M | Sep 29, 2025 |
| HBK Investments L P | 3.76% | 2,850,000 | 256.50M | Sep 29, 2025 |
| FMR, LLC | 3.71% | 2,810,935 | 252.98M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 0.84% | 640,000 | 57.60M | Oct 30, 2025 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 0.82% | 620,890 | 55.88M | Sep 29, 2025 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 0.78% | 593,000 | 53.37M | Oct 30, 2025 |
| Columbia Funds Series Trust I-Columbia Cornerstone Growth Fund | 0.67% | 509,004 | 45.81M | Oct 30, 2025 |
| SmallCap World Fund Inc | 0.65% | 491,244 | 44.21M | Sep 29, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.54% | 412,869 | 37.16M | Oct 30, 2025 |